Bladder cancer is a prevalent and challenging malignancy, affecting thousands of individuals worldwide each year. A groundbreaking advancement in the field of cancer therapy has the potential to transform the way we address this disease – photothermal therapy (PTT). As a premier preclinical CRO, Alfa Cytology offers comprehensive services in the development and evaluation of PTT-based treatments for bladder cancer.
Bladder cancer is a complex and persistent disease that has long posed significant challenges for healthcare professionals. Conventional treatment approaches, such as surgery, chemotherapy, and radiation, have had limited success, often leading to significant side effects and suboptimal outcomes. PTT harnesses the power of light-absorbing nanomaterials to selectively destroy cancer cells, while leaving healthy tissues unharmed.
Fig 1. Schematic representation of NIR-II optical imaging and non-invasive interventional photothermal therapy for bladder cancer. (Hong F., et al. 2022)
At the core of PTT are strategically engineered nanomaterials, such as gold nanoparticles, carbon nanotubes, and metal-organic frameworks, that can efficiently convert near-infrared (NIR) light energy into localized heat. When these nanomaterials are selectively accumulated within bladder tumors, the application of NIR light triggers a controlled thermal ablation, inducing the death of cancer cells through apoptosis and necrosis.
Compared to traditional therapy, PTT offers several key advantages:
At Alfa Cytology, utilize our proprietary nanoparticle manufacturing technology to provide solutions for the rapid development of photothermal therapeutics for bladder cancer. With our extensive expertise in nanoparticle fabrication and biofunctionalization for targeted delivery, controlled release, photothermal therapies and more, we help our partners bring high-impact nanotherapeutic products to the bladder cancer treatment market.
Photothermal Therapeutic Agents Development Workflow
|
|||
We offer a wealth of bladder cancer models for evaluating the biocompatibility and efficacy of photothermal therapeutic agents.
In Vitro Evaluation
In Vivo Preclinical Studies
If you are interested in exploring the potential of photothermal therapy for bladder cancer, we invite you to contact Alfa Cytology. Our team of experts is ready to collaborate with you and provide tailored solutions to address your specific research needs. Together, we can unlock the full potential of this groundbreaking approach and pave the way for more effective bladder cancer therapy.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.